Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.
It was patented in 1971 and came into medical use in 1983.[1]
Contents
1Medical use
2Mode of action
3Pharmacokinetics
4Adverse effects
5References
6External links
Medical use
Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[2][3]
Mode of action
Further information: Beta2-adrenergic agonist
Pharmacokinetics
After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]
Adverse effects
Further information: Beta2-adrenergic agonist
References
^Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 543. ISBN 9783527607495.
^ ab"Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Retrieved 7 March 2016.
^Bianchi, Marina; Clavenna, Antonio; Bonati, Maurizio (2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period". European Journal of Clinical Pharmacology. 66 (9): 929–936. doi:10.1007/s00228-010-0845-y. ISSN 0031-6970.
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.
v
t
e
English Journal
Structural characterization of electrochemically and in vivo generated potential metabolites of selected cardiovascular drugs by EC-UHPLC/ESI-MS using an experimental design approach.
Szultka-Młyńska M, Bajkacz S, Baranowska I, Buszewski B.
Talanta. 2018 Jan;176()262-276.
In the last few years, a number of studies were conducted which aimed at understanding the mechanisms of cardiovascular drug, metabolism, and there is still the need to determine the metabolites of cardiac drugs for the purpose of metabolism control. In this study, we employ a direct combination of
Broad screening and identification of β-agonists in feed and animal body fluid and tissues using ultra-high performance liquid chromatography-quadrupole-orbitrap high resolution mass spectrometry combined with spectra library search.
Li T, Cao J, Li Z, Wang X, He P.
Food chemistry. 2016 Feb;192()188-96.
Broad screening and identification of β-agonists in feed, serum, urine, muscle and liver samples was achieved in a quick and highly sensitive manner using ultra high performance liquid chromatography-quadrupole-orbitrap high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) combined with a spect
Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000-2009 period.
Bianchi M, Clavenna A, Bonati M.
European journal of clinical pharmacology. 2010 Sep;66(9)929-36.
The objective of this study was to analyse inter-and intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents. A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000
Pirbuterol - Get up-to-date information on Pirbuterol side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Pirbuterol ... Pirbuterol may cause serious side effects, including: worsening trouble breathing ...